GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Non-Small Cell Lung Cancer
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
GEMINI-NSCLC: NSCLC Biomarker Study
-
Alabama Oncology, Birmingham, Alabama, United States, 35223
Mercy Clinic Oncology - Fort Smith, Fort Smith, Arkansas, United States, 72903
MemorialCare, Fountain Valley, California, United States, 92708
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States, 90720
Eastern CT and Hematology and Oncology Associates, Norwich, Connecticut, United States, 06360
Woodlands Medical Specialists, Pensacola, Florida, United States, 32503
Morehouse School of Medicine (MSM), Atlanta, Georgia, United States, 30310
Hawaii Cancer Care, Honolulu, Hawaii, United States, 96813
Southern Illinois Hospital Services, Carterville, Illinois, United States, 62918
Cancer Care Specialists of Illinois, Decatur, Illinois, United States, 62526
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Tempus AI,
Virginia Rhodes, MD, PRINCIPAL_INVESTIGATOR, Tempus AI, Inc.
2029-06